About Careers MedBlog Contact us
Medindia LOGIN REGISTER
Advertisement

Novel Treatment for Prostate Cancer Shows Great Efficacy in Mouse Models

by Dr. Trupti Shirole on March 23, 2016 at 8:05 AM
Font : A-A+

 Novel Treatment for Prostate Cancer Shows Great Efficacy in Mouse Models

Besides non-melanoma skin cancer, prostate cancer is the most common cancer among men in the U.S., suggests the Centers for Disease Control and Prevention. It is also one of the leading causes of cancer death among men of all races.

Researchers at the University of Georgia have created a new therapeutic for prostate cancer that has shown great efficacy in mouse models of the disease. They published their findings recently in the journal Nanomedicine: Nanotechnology, Biology and Medicine.

Advertisement


The treatment is designed to inhibit the activity of a protein called PAK-1, which contributes to the development of highly invasive prostate cancer cells.

"PAK-1 is kind of like an on/off switch," said study co-author Somanath Shenoy, an associate professor in UGA's College of Pharmacy. "When it turns on, it makes cancerous cells turn into metastatic cells that spread throughout the body."
Advertisement

With the help of Brian Cummings, an associate professor in UGA's College of Pharmacy, the researchers developed a way to package and administer a small molecule called IPA-3, which limits the activity of PAK-1 proteins.

They enveloped the IPA-3 molecule in a bubble-like structure called a liposome and injected it intravenously. The liposome shell surrounding IPA-3 ensures that it is not metabolized by the body too quickly, allowing the inhibitor enough time to disrupt the PAK-1 protein.

The researchers found that this molecule significantly slowed the progression of cancer in mice, and it also forced the cancerous cells to undergo apoptosis, a kind of programmed cell death.

"When we first began these experiments, we injected IPA-3 directly into the bloodstream, but it was absorbed so quickly that we had to administer the treatment seven days a week for it to be effective," Shenoy said. "But the liposome that Dr. Cummings created makes the IPA-3 much more stable, and it reduced the treatment regimen to only twice a week."

The preliminary results suggest that IPA-3 might be a viable treatment for prostate cancer in humans, but Shenoy cautions that much work must be done before human clinical trials can begin.

"The results of our experiments are promising, and we hope to move toward clinical trials soon," he said, "but we must figure out what side effects this treatment may have before we can think about using it in humans."

Source: Eurekalert
Advertisement

Advertisement
News A-Z
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
What's New on Medindia
Test  Your Knowledge on Heart
Test Your Knowlege on Genes
Obesity in Teens Make Inroads into Early Atrial Fibrillation
View all
Recommended Reading
News Archive
Date
Category
Advertisement
News Category

Medindia Newsletters Subscribe to our Free Newsletters!
Terms & Conditions and Privacy Policy.

More News on:
Prostate Cancer Cancer and Homeopathy Trans-Urethral Resection of the Prostate Prostate Cancer Facts Cancer Facts Cancer Tattoos A Body Art Prostate Cancer: Treatment Options Prostate Specific Antigen [PSA] Nutrition All Men Need 

Most Popular on Medindia

Find a Hospital Blood - Sugar Chart Blood Pressure Calculator Blood Donation - Recipients Post-Nasal Drip Selfie Addiction Calculator Iron Intake Calculator Pregnancy Confirmation Calculator A-Z Drug Brands in India Diaphragmatic Hernia
This site uses cookies to deliver our services. By using our site, you acknowledge that you have read and understand our Cookie Policy, Privacy Policy, and our Terms of Use
×

Novel Treatment for Prostate Cancer Shows Great Efficacy in Mouse Models Personalised Printable Document (PDF)

Please complete this form and we'll send you a personalised information that is requested

You may use this for your own reference or forward it to your friends.

Please use the information prudently. If you are not a medical doctor please remember to consult your healthcare provider as this information is not a substitute for professional advice.

Name *

Email Address *

Country *

Areas of Interests